Clinical Trial

Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.

Study acronym: DAHLIA
Recruiting
View on ClinicalTrials.gov →
Summary
This is an observational, multicenter, prospective study on patients with systemic lupus erythematosus treated with anifrolumab in Italy aimed at evaluating the achievement of LLDAS5
Protocol Amendment History 1 change
notable Trial sites expanded: 19 -> 22 locations 2026-06-26
Trial Details
NCT Number NCT07330245
Lead Sponsor AstraZeneca
Conditions Lupus Erythematosus, Systemic
Enrollment 218 participants
Start Date 2025-12-31
Primary Completion 2028-09-30 (estimated)
Study Completion 2028-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-22